Stock COYA COYA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Coya Therapeutics, Inc.

Equities

COYA

US22407B1089

Market Closed - Nasdaq
Other stock markets
 21:00:00 24/05/2024 BST 		5-day change 1st Jan Change
7.91 USD -2.94% Intraday chart for Coya Therapeutics, Inc. -6.94% +6.75%
05-20 Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation MT
05-17 Coya Therapeutics, Inc. announced that it expects to receive $4.999997 million in funding from Alzheimers Drug Discovery Foundation CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 in Patients with Alzheimer's disease
AQ
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
BU
Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation
MT
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
BU
Coya Therapeutics, Inc. announced that it expects to receive $4.999997 million in funding from Alzheimers Drug Discovery Foundation
CI
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
BU
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
BU
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
BU
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
BU
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
BU
Chardan Ups PT on Coya Therapeutics to $14 From $11 on Advancements of COYA 302 Targeting Multiple Neurodegenerative Diseases, Keeps Buy Rating
MT
Coya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
BU
Coya Therapeutics to Participate in BTIG Fireside Discussion
BU
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
BU
Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
CI
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia at the AD/PD 2024 Conference
AQ
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
BU
Coya Therapeutics to Present Data on Immune System and Regulatory T cell Contributions in Frontotemporal Dementia Patients at AD/PD 2024 Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COYA Stock
  4. News Coya Therapeutics, Inc.